DefiniGEN offer a unique range of validated human cell disease models and predictive bioassays to measure efficacy of compounds and gene therapies against liver diseases. Our unique platform and know how allows our clients to perform screening to triage their therapeutic molecules and evaluate delivery methodologies. Our iPSC-derived hepatocytes are the most highly predictive, phenotypically relevant human models available to support development of therapies against a range of indications.